Evidence map›Paper›PMID 39191543›Full record

ReviewTrends in immunology2024

Nanocarrier design for pathogen-inspired innate immune agonist delivery.

Griffin I Kane, Meghan L Brassil, Miranda B Diaz-Infante, Prabhani U Atukorale

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Griffin I KaneDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA; UMass Cancer Center, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Meghan L BrassilDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA; UMass Cancer Center, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Miranda B Diaz-InfanteDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA; UMass Cancer Center, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Prabhani U AtukoraleDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA; Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA; Division of Innate Immunity, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA; UMass Cancer Center, University of Massachusetts Chan Medical School, Worcester, MA, USA. Electronic address: patukorale@umass.edu.

Funding

Designing a targeted 'super adjuvant' nanoparticle platform for vaccinationR21EB034465 · NIBIB · UNIVERSITY OF MASSACHUSETTS AMHERST · PI ATUKORALE, PRABHANI · 2023 to 2025
$637k
Tumor-directed immunostimulatory nanoparticles for novel 'prime-pull'cancer vaccinationK22CA262355 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI ATUKORALE, PRABHANI · 2021 to 2023
$583k
NCI NIH HHS K22 CA262355NIBIB NIH HHS R21 EB034465
6 · The paper itself

Abstract

In complex diseases such as cancer, modulating cytokine signatures of disease using innate immune agonists holds therapeutic promise. Novel multi-agonist treatments offer tunable control of the immune system because they are uniquely pathogen inspired, eliciting robust antitumor responses by promoting synergistic cytokine responses. However, the chief strategic hurdle is ensuring multi-agonist delivery to the same target cells, highlighting the importance of using nanomaterial-based carriers. Here, we place nanocarriers in center stage and review the delivery hurdles related to the varying extra- and intracellular localizations of innate immune receptors. We discuss a range of nanomaterials used for multi-agonist delivery, highlighting their respective benefits and drawbacks. Our overarching stance is that rational nanocarrier design is crucial for developing pathogen-inspired multi-agonist immunotherapies.

Indexed as

Immunity, InnateAnimalsCytokinesDrug CarriersDrug Delivery SystemsHumansImmunotherapyNanoparticlesNanostructuresNeoplasmsCytokinesDrug Carrierscancer immunoengineering, drug deliveryinnate immunitynanoparticlespathogen-inspired technologiessynergistic cytokine production

Identifiers

PMID39191543
PMCPMC11492413

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.